GLP-1 Kidney Problems: What Helps, What Hurts, and What Applies to You

By Weight Loss Provider Guide · Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.

Last verified: August 11, 2026 · 9 currently marketed stand-alone U.S. brand-label records and 2 withdrawn exenatide reference labels reviewed

This page is for education. It cannot diagnose a kidney problem or tell you what to do with your next dose. Tirzepatide is a dual GIP/GLP-1 medicine, but it is included because patients and clinicians commonly group it with GLP-1 drugs.

GLP-1 kidney problems are real — but they are not one thing, and they do not all point the same direction.

Here is the short version. In a large VA observational study, GLP-1 users had less acute kidney injury and less chronic kidney disease than people on other diabetes drugs. The same study, same people, same time period, also found more kidney stones and more interstitial nephritis. And semaglutide injection, sold as Ozempic, now carries an FDA-approved indication to reduce the risk of kidney disease getting worse in adults with type 2 diabetes and chronic kidney disease.

So the honest answer depends on three things: which kidney problem you mean, which drug you take, and whether you can keep fluids down.

That last one is the big one. The current warning across the nine active label records we reviewed is not “this drug attacks your kidneys.” It is that vomiting, diarrhea, or barely drinking can drain enough fluid from your body to hurt your kidneys — and some reported cases have needed dialysis.

If you are vomiting right now, or cannot keep water down, stop reading and use the box below. Everything else on this page can wait.

For everyone else, we put the kidney language from nine currently marketed stand-alone U.S. brand-label records beside the two exenatide reference labels that were withdrawn in 2025. The current labels have no hard kidney-function cutoff. The two withdrawn exenatide labels do: creatinine clearance below 30 for Byetta and eGFR below 45 for Bydureon BCISE. FDA-approved generic exenatide still carries Byetta's below-30 rule.

That is the useful answer above the fold. The rest of this page shows where it comes from, what it does not prove, and what to do with your own symptoms or lab result.

Start here: what should you do right now?

We are not going to give you a symptom checklist here. If you want the full “is this an emergency?” walkthrough, use our separate guide: When to message your GLP-1 provider about side effects →

One thing we will not do anywhere on this page: tell you to skip, stop, lower, or restart a dose. That decision needs your labs, your history, and a licensed clinician. Not an article.

Can GLP-1 drugs cause kidney problems?

Yes — but “kidney problems” covers several different conditions, and the signals move in different directions. In a VA study of more than 1.4 million people with type 2 diabetes, GLP-1 users had lower rates of acute kidney injury and chronic kidney disease, and higher rates of kidney stones and interstitial nephritis, compared with people receiving usual diabetes care. The study was observational, so it found associations. It did not prove that GLP-1 drugs caused or prevented each outcome.

The four outcomes, from one study

Most of what you have read about this comes from a headline that picked one number. Here is the full kidney picture from the same study, so nothing gets cherry-picked.

Researchers compared 215,970 GLP-1 users with 1,203,097 people receiving usual diabetes care. Median follow-up was about 3.7 years. They mapped 175 health outcomes. Four were kidney outcomes.

Source: Xie Y, Choi T, Al-Aly Z. “Mapping the effectiveness and risks of GLP-1 receptor agonists.” Nature Medicine, 2025.

A hazard ratio under 1.00 means a lower rate in the GLP-1 group. A number over 1.00 means a higher rate. So 0.88 is about 12% lower, and 1.15 is about 15% higher.

Why this table matters: some headlines led with the two increases and gave much less space to the two decreases. Same study. Same people. Same follow-up. If you saw only the scary half, you saw half the result.

What this does not mean

• It does not prove the medicine directly injured or protected kidney tissue. The study was not randomized.
• It does not mean everyone gets kidney problems. These are population-level shifts, not a prediction about you.
• It does not mean one lab result equals permanent damage.
• It does not mean every GLP-1 behaves the same. They do not. That is why the label table matters.

The honest limit on this data

The VA study population was 94.7% male, had an average age of 68.6, and had type 2 diabetes. That is not most of the people reading this page. It is a huge dataset, and it is useful — but it is not a direct answer for a 41-year-old woman using a GLP-1 only for weight loss.

And the part we cannot smooth over

The common label warning centers on fluid loss. But not every published kidney case fits a simple dehydration story. Case reports describe acute kidney injury and biopsy-proven interstitial nephritis after semaglutide use. Case reports cannot tell us how often this happens, and they cannot prove a population-wide cause. They do prove that “just drink more water” is too simple when kidney function changes.

That is why the second row at the top says call your prescriber and not hydrate and wait.

Why do some studies say GLP-1s protect your kidneys and others say they hurt them?

Because the answer changes with the comparison. Against placebo, semaglutide lowered a major kidney-and-cardiovascular composite by 24% in people with type 2 diabetes and chronic kidney disease. Against SGLT2 inhibitors — a drug class with strong kidney-outcome evidence — GLP-1 medicines had more chronic kidney disease and acute kidney injury in a five-year observational comparison. Those studies asked different questions.

This is the single most misunderstood part of the topic. Once you see the comparison column, the conflict makes sense.

The sentence the scary headline needs

“GLP-1 users had 8.2% chronic kidney disease versus 6.7%” sounds very different once you know the comparison group was taking SGLT2 inhibitors.

SGLT2 inhibitors include medicines such as Jardiance and Farxiga. They have strong randomized evidence for slowing kidney disease and are recommended in modern CKD guidance for many eligible patients. Losing a kidney-outcome comparison to that class does not prove a GLP-1 harms healthy kidneys.

The part that keeps this honest

We are not going to spin the Jensen study away. It found that SGLT2 inhibitors did better on chronic kidney disease and acute kidney injury over five years. If kidney protection is the main treatment goal and a clinician is choosing between the two classes, that matters.

The same study found slightly less albuminuria and lower mortality in the GLP-1 group. Two drug classes can have different strengths. Clinicians also use them together when a patient's condition, medicines, and coverage allow it.

How to read any GLP-1 kidney headline from now on

Ask one question: compared with what?

• Compared with placebo in type 2 diabetes plus CKD → semaglutide lowered major kidney/CV events.
• Compared with usual diabetes care → the VA study found lower acute injury and CKD, but higher stones and nephritis.
• Compared with SGLT2 inhibitors → GLP-1 medicines came second on CKD and acute injury in an observational comparison.
• Compared with your own kidneys 20 years from now → that study does not exist for most healthy weight-loss users.

That last line is not a throwaway. It is the next section.

Our one honest admission before we go further

We cannot tell you that a GLP-1 will protect your kidneys.

The trial that produced the FDA kidney indication — FLOW — studied people who had type 2 diabetes and existing kidney disease, at a dose of 1.0 mg of semaglutide. That is a diabetes dose. The common Wegovy weight-loss dose is 2.4 mg. Different dose. Different patients. Different question.

If you do not have diabetes and your kidneys are healthy, no one has run the trial that tells you what this medicine does to your kidneys over 20 years. Anyone who gives you a certain answer is guessing or selling.

Here is what we can tell you, and it is the part that can change your outcome:

All nine currently marketed stand-alone label records we reviewed warn about kidney injury connected to fluid loss from stomach side effects. That is the piece you can plan around. Knowing which symptoms to report, which numbers to track, and what your exact label says is worth more right now than a 20-year projection nobody has.

The rest of this page is that information.

How does dehydration from a GLP-1 hurt the kidneys?

GLP-1 medicines can cause nausea, vomiting, or diarrhea, especially when treatment starts or the dose rises. If you lose enough fluid, less blood reaches your kidneys and filtering can fall. Current labels describe postmarketing cases of acute kidney injury, sometimes requiring dialysis, most often after stomach reactions led to dehydration.

It can happen in four steps:

1. The medicine makes you nauseated, you vomit, you have diarrhea, or you eat and drink much less.
2. You lose more fluid than you take in.
3. The amount of blood circulating through your body falls.
4. Less blood reaches the kidneys. Creatinine can rise and eGFR can fall.

Your kidneys are filters that need blood flow to work. Take away enough fluid and you take away part of that flow.

Why starting and raising a dose are the risky moments

Current semaglutide and tirzepatide labels tell prescribers to monitor kidney function when a patient reports reactions that could cause fluid loss, especially during initiation and dose escalation. Stomach side effects also tend to cluster during dose escalation.

So pay closest attention during the first weeks of treatment and after a dose increase. That does not mean a problem will happen. It means those are the moments when persistent vomiting, diarrhea, or very low intake should not be brushed off.

Who has less room for error

• People who already have chronic kidney disease
• People with a fluid limit set by their kidney or heart team
• People who are sick with something else at the same time — a stomach bug, fever, or heat illness
• People taking other medicines that affect blood pressure, kidney blood flow, or fluid balance

Bring your complete medicine and supplement list to the prescriber. Do not stop any of it on your own because of something you read here.

Can a GLP-1 protect your kidneys and still cause kidney injury?

Yes. Short-term kidney injury from fluid loss and long-term kidney protection describe different time frames, mechanisms, and groups of people. Ozempic's current FDA label carries both an acute kidney injury warning and a kidney-protection indication.

Read that again, because it is the whole puzzle in one sentence: the same label carries both.

The short-term risk

You get sick, lose fluid, and kidney filtering drops. Days to weeks. Often reversible when the cause is found and treated. Sometimes serious.

The long-term benefit

On January 28, 2025, FDA approved Ozempic to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. It remains the only product in this comparison with an FDA kidney-protection indication.

In FLOW, 18.7% of the semaglutide group and 23.2% of the placebo group had a primary event. That is a 4.5 percentage-point absolute difference over a median 3.4 years. Serious adverse events were lower with semaglutide than placebo: 49.6% vs 53.8%.

What REMODEL added — and what it did not prove

FLOW showed that outcomes improved. It did not settle one exact reason why.

REMODEL was a 52-week, 106-person phase 3b trial in people with type 2 diabetes and CKD. It used advanced kidney MRI, blood and urine markers, and paired kidney biopsies in a smaller subgroup. The study was built to look for mechanisms, not to prove long-term kidney-failure prevention.

Results reported in 2026 gave mechanistic clues involving kidney fat, blood flow and glomerular hemodynamics, and endothelial and metabolic pathways. That is valuable. It is not proof that one pathway explains the entire FLOW benefit, and it does not turn a small mechanistic trial into a long-term outcomes trial.

REMODEL was funded by Novo Nordisk, the company that makes semaglutide. We are telling you that because funding belongs beside the result, not hidden at the bottom.

The useful way to hold both ideas

A treatment can lower long-term disease risk and still create a short-term risk under specific conditions. Blood thinners do this. Surgery does this. Many useful treatments do.

The benefit does not erase the warning. The warning does not erase the benefit. The practical goal is to catch severe stomach symptoms and fluid loss early enough that the short-term problem does not steal the long-term benefit.

Which GLP-1 has the strictest kidney rules?

The strictest current rule is on FDA-approved generic exenatide, which follows the former Byetta label: it is not recommended with severe kidney impairment or end-stage kidney disease, defined there as creatinine clearance below 30 mL/min. The withdrawn Bydureon BCISE label used a stricter eGFR cutoff of 45. None of the nine currently marketed stand-alone brand-label records in our table has a hard kidney-function cutoff.

This is the table we built the page around.

First, what our 11 rows do — and do not — count

Our review covers nine currently marketed stand-alone U.S. brand-label records most relevant to people searching for GLP-1 or tirzepatide kidney rules, plus the two withdrawn exenatide reference labels that still appear in old articles and patient discussions.

We did not count every generic duplicate as a separate row. We did not count fixed-ratio insulin combinations such as Soliqua or Xultophy as stand-alone GLP-1 products. We also excluded discontinued stand-alone brands from the marketed comparison. FDA-approved generic exenatide remains available and carries Byetta's kidney restriction. Byetta and Bydureon BCISE themselves were no longer marketed, and FDA withdrew their approvals effective September 3, 2025.

The GLP-1 kidney rulebook

Sources: current and archived FDA-approved prescribing information on DailyMed, plus the Federal Register withdrawal notice. Verified August 11, 2026.

Three things fall out of this table that are easy to miss anywhere else.

1. “No cutoff” is not the same claim as “proven safe on dialysis”

Nine currently marketed records have no hard eGFR or creatinine-clearance cutoff. But the wording is not identical.

Ozempic, oral semaglutide, tirzepatide, Foundayo, and Trulicity give clear no-adjustment or no-modification language. Victoza and Saxenda call out limited ESRD experience. Wegovy's current merged label has no hard cutoff, but it also no longer gives the broad ESRD dose sentence found in an older U.S. label; its current PK analysis describes eGFR 30 to under 90.

That is why we separated hard cutoff, dose wording, and dialysis evidence instead of turning them into one fake “safe at every stage” column.

2. Exenatide is the real kidney-clearance exception

Exenatide depends heavily on kidney clearance. When kidney filtering drops, exposure rises. The former Byetta label reported exposure about 3.37 times higher in dialysis patients, and a small dose was poorly tolerated because of stomach effects.

The two exenatide formulations did not even use the same threshold: Byetta used CrCl below 30; Bydureon BCISE used eGFR below 45. That is why any article that says “exenatide's cutoff is 30” without naming the formulation is incomplete.

3. Same molecule does not guarantee the same label sentence

Semaglutide: Ozempic has a kidney-protection indication. Wegovy does not. The indication follows the population, dose, and outcome trial submitted for that product — not just the molecule name.

The same issue appears in renal wording. Ozempic's current label gives a clear no-adjustment statement including kidney failure. Wegovy's current merged label has no hard cutoff but uses narrower PK wording.

The label tracks the approved evidence package. It is not a molecule-wide promise.

Why we will not name a “kidney safest” GLP-1

The labels were not built for a head-to-head kidney-safety ranking. Each product was tested in different people, at different doses, over different periods. FDA labels warn that adverse-event rates from separate trials cannot be compared as if the trials were one race.

Anyone turning those separate percentages into a clean safest-to-riskiest list is doing arithmetic the evidence does not support.

Save your drug's exact rule before you call

Write down four things from the table: product name, hard cutoff, exact dose wording, and what the label says about severe CKD or dialysis. Bring those four lines to the clinician who manages the prescription.

Need help wording the message? Use when to message your GLP-1 provider about side effects →

What changed in GLP-1 kidney warnings in 2025?

The wording became more consistent and more direct. The kidney risk itself was not newly discovered in 2025, and older patient leaflets were not universally silent about it. Archived FDA labels from 2024 already described acute kidney injury or renal failure tied to nausea, vomiting, diarrhea, and dehydration — sometimes requiring hemodialysis.

The scary version of this story says people who started Byetta, Victoza, Saxenda, Trulicity, or Mounjaro before mid-2025 had leaflets that did not warn them. Older FDA labeling does not support that class-wide claim.

What older labels already said, and what current labels make clearer

Why the new wording feels like a new danger

“Acute kidney injury due to volume depletion” is blunt. It puts the injury and the mechanism in the heading instead of making the reader connect several paragraphs.

That is useful. It is also easy to misread as proof that FDA discovered a brand-new kidney problem in 2025. The archived labels show otherwise.

What this was not: a kidney recall, proof that the manufacturers hid 20 years of data, or evidence that every earlier Medication Guide omitted the risk.

What it was: clearer, more standardized language that makes the dehydration pathway harder to miss.

If you have an old paper insert, use the current FDA-approved prescribing information and Medication Guide for the exact product you take. Do not assume the paper in a years-old box is the current version.

Can you take a GLP-1 if you already have chronic kidney disease?

For the nine currently marketed stand-alone brand-label records in our table, chronic kidney disease is not blocked by a hard kidney-function cutoff. FDA-approved generic exenatide is the important current exception: it follows Byetta's “not recommended below CrCl 30 or in ESRD” rule. The withdrawn Bydureon BCISE label used eGFR below 45. But “the label allows it” is not the same as “it is right for you.”

Chronic kidney disease is not one number

Doctors describe kidney filtering with eGFR, or estimated glomerular filtration rate. CKD means an abnormality in kidney structure or function has been present for at least three months and matters to health.

That time rule matters. A low eGFR during three days of vomiting is not automatically chronic kidney disease. It may be an acute change. It still needs attention, but it answers a different question.

The eGFR stages people actually mean

The “other marker” may be albumin in the urine, an imaging finding, a structural problem, or another persistent sign of kidney damage. That is why “my eGFR is 82” does not diagnose CKD by itself.

The 45 rule people keep applying to the wrong drug

We found a recurring concern in kidney-patient communities: someone reads that eGFR below 45 means a medicine should not be used, then applies that rule to the entire GLP-1 class.

There are two reasons that goes wrong.

First, 45 was Bydureon BCISE's product-specific cutoff, not a class cutoff. Byetta and generic exenatide use a different measure and threshold: creatinine clearance below 30.

Second, older or indication-specific SGLT2 instructions also used higher eGFR thresholds. That is not a universal current SGLT2 rule either. Modern KDIGO guidance recommends SGLT2 treatment for many adults with CKD at an eGFR of 20 or higher, depending on the clinical situation.

If a single number is the reason you think you are disqualified, ask which exact drug, formulation, indication, and label that number came from.

The U.S., Canada, and UK wording is not identical

Here is an uncertainty worth showing instead of hiding:

These are not “three regulators reaching three verdicts.” The UK item is professional pharmacy guidance, not a regulator. The documents also use different evidence thresholds and were revised at different times.

If your clinician is more cautious than a U.S. label, this difference may be part of the reason. It is a better conversation starter than an argument.

Questions worth asking if you have CKD

• What is my most recent eGFR, and what was it before that?
• What is my urine albumin-to-creatinine ratio?
• Do I have a fluid limit?
• What kidney monitoring fits my stage, symptoms, and other medicines?
• What exactly should I do if I get a stomach bug?
• Which member of my care team should make the call if my kidney numbers change?

What about dialysis and kidney transplants?

Neither is an automatic no for every GLP-1 medicine, but both sit at the edge of the evidence. Several current labels report little pharmacokinetic change in ESRD. That does not equal a long dialysis outcomes trial. Exenatide is the clear exception, and any decision for a dialysis or transplant patient belongs with the kidney and transplant teams.

On dialysis

Drug-level data can answer whether kidney failure makes a medicine build up. It cannot tell you what happens to nutrition, fluid balance, side effects, hospitalizations, or quality of life over a year on dialysis.

Two practical issues rarely get enough space:

Fluid. Many people on dialysis have a strict fluid limit. General “drink plenty of water” advice can be actively wrong. Any hydration plan has to come from the kidney team.

Protein and nutrition. Dialysis can increase protein needs. A medicine that sharply lowers appetite can create a real conflict. Poor intake can lead to weakness and malnutrition faster in a person already managing dialysis.

There is also a reason this question comes up so often: some transplant programs use body-size criteria. For some people, medically supervised weight loss may help them become eligible or safer for surgery. That is a legitimate goal, but it belongs inside a transplant plan — not a generic telehealth intake.

Exenatide is the clear exception. FDA-approved generic exenatide is not recommended in ESRD. The former Byetta label reported that even a single 5 mcg dose was poorly tolerated in dialysis patients. The withdrawn Bydureon BCISE label was also not recommended in ESRD.

After a kidney transplant

The evidence got better in 2025, but it is still observational.

A Lancet Diabetes & Endocrinology cohort followed 18,016 kidney transplant recipients with pre-existing type 2 diabetes. Of them, 1,969 started a GLP-1 receptor agonist after transplant. GLP-1 use was associated with a 49% lower adjusted incidence of death-censored graft loss and a 31% lower adjusted risk of death.

That is not “49% lower odds,” and it is not proof the medicine caused the benefit. In matched groups, five-year graft loss was 6.0% among users and 10.7% among non-users. A randomized transplant trial is still needed.

A separate series of 185 kidney transplant recipients found stable kidney function and no significant change in median tacrolimus levels during GLP-1 treatment. That is reassuring, not a promise.

The thing transplant teams watch is tacrolimus and other narrow-range anti-rejection medicines. GLP-1 drugs slow stomach emptying, so absorption is a reasonable monitoring concern even when no confirmed interaction has been shown. This is a “your team checks it” issue, not a “no problem” issue.

The former Byetta label specifically told clinicians to use caution after kidney transplant.

What do creatinine, eGFR, BUN, and uACR actually mean?

Creatinine and eGFR estimate filtering. BUN adds context about waste, food intake, and hydration. uACR measures albumin leaking into urine and can find kidney damage that eGFR misses. A single result is a clue, not a full diagnosis — the trend, symptoms, and baseline matter.

If you got a lab result and panicked, this section is the one you came for.

Serum creatinine

Creatinine is a waste product linked to normal muscle activity. Healthy kidneys remove it. When filtering slows, the blood level can rise.

What can move it besides lasting kidney damage: dehydration, acute illness, muscle mass, hard exercise, and recent meat intake. That is why your own baseline matters more than a random “normal” number from someone else.

eGFR

eGFR is calculated from creatinine plus factors such as age and sex. It is an estimate, not a direct measurement — the “e” means estimated.

The correct map is not simply “90 normal, under 90 damaged.” G1 and G2 count as CKD only when another marker of kidney damage is present. G3a begins at 45–59, G3b at 30–44, G4 at 15–29, and G5 below 15.

The mistake people make: treating one low eGFR as a permanent diagnosis. CKD requires a persistent abnormality for at least three months. A sudden drop during vomiting, diarrhea, fever, or another illness may be acute and still needs clinical follow-up.

BUN

Blood urea nitrogen is another waste measurement. It changes with kidney function, hydration, protein intake, bleeding in the digestive tract, and other factors.

Clinicians sometimes look at the BUN-to-creatinine ratio for context. A high ratio can fit dehydration, but it cannot prove dehydration by itself.

uACR

uACR means urine albumin-to-creatinine ratio. Albumin is a blood protein. When too much appears in urine, the kidney filters may be leaking.

Why this one matters here: uACR can show kidney damage before eGFR changes. It is also the measure where several GLP-1 studies show the clearest improvement.

The 101-person randomized trial in adults with overweight or obesity and CKD without diabetes found a placebo-corrected 52.1% reduction in uACR at 24 weeks with semaglutide 2.4 mg. That is an albuminuria result, not proof of less kidney failure over decades.

If you have diabetes or known kidney disease and nobody has checked uACR, that is a fair question to raise.

Quick reference

The monitoring myth we need to correct

You will read on popular sites that everyone taking a GLP-1 needs kidney labs every three to six months.

Our August 11, 2026 label review found that 0 of the 9 currently marketed stand-alone brand-label records sets a universal every-three-to-six-month kidney testing schedule.

What the labels do say is to monitor kidney function when a patient reports reactions that could cause fluid loss. Several specifically call out initiation and dose escalation. That is a trigger-based label instruction, not a universal calendar.

Your clinician may still choose routine testing because of CKD, diabetes, age, blood-pressure medicines, prior injury, or another risk. That can be good care. It is an individual plan, not a schedule printed across the class.

My creatinine went up after starting a GLP-1. What now?

Contact the clinician who prescribed it and bring a timeline, not just one number. The most useful thing you can do is show when symptoms started relative to your doses, what your urine has been doing, and what your kidney numbers were before. Do not decide about your next dose from a lab result and an article.

Here is what turns a vague worried call into a useful one.

Build the timeline before you call

Write down:

• Which medicine you take, including injection or tablet
• The date you started
• Your current prescribed dose
• The date of your last dose
• The date of your most recent dose increase
• When nausea, vomiting, diarrhea, or low appetite began
• Any change in how much or how dark your urine is
• Your previous creatinine and eGFR, with dates
• Your new creatinine and eGFR, with dates
• Any other recent illness, fever, heavy exercise, or heat exposure
• Every medicine and supplement you take

That last one is not filler. Common medicines can change kidney blood flow, blood pressure, potassium, or fluid balance. Your prescriber needs the whole list to sort out what happened.

The four questions that get you a real answer

1. “Could fluid loss explain this, or do we need to look for another cause?”
2. “How does this compare with my baseline?”
3. “Should the test be repeated, and how soon?”
4. “Given my symptoms and numbers, what should I do before my next scheduled dose?”

We are deliberately not answering number four. There is no responsible universal answer. It depends on how sick you are, your kidney function, the medicine and dose, and everything else you take.

When a kidney specialist enters the picture

If a kidney change is severe, persistent, or unexplained, your prescriber may involve a nephrologist. That is not proof things have gone badly wrong. It means the cause or recovery needs a kidney specialist's attention.

There is no single referral threshold that fits every patient, and a website should not invent one.

Copy-ready prescriber worksheet

Copy this into your phone or patient portal. Nothing is stored on this site.

Medicine and form:
Current prescribed dose:
Start date:
Last dose date:
Last dose increase date:
Symptoms and start dates:
Urine changes:
Old creatinine / eGFR / date:
New creatinine / eGFR / date:
Recent illness, heat, or heavy exercise:
Other medicines and supplements:
My four questions: Could fluid loss explain this? How does it compare with baseline? When should it be repeated? What should I do before the next scheduled dose?

Do GLP-1s cause kidney stones?

There is a modest stone signal, but the cause is not proven. The VA study found a 15% higher rate of nephrolithiasis in GLP-1 users than in usual-care users. The current Wegovy label also reports urolithiasis in 1.2% of treated patients versus 0.8% on placebo in one cardiovascular outcomes trial.

That does not mean every stone was caused by the medicine. The VA result was observational, and the Wegovy number came from one trial.

One plausible explanation is lower fluid intake. People may drink less because they feel full, nauseated, or uninterested in food and drinks. Low urine volume is a known stone risk. But the VA study did not establish why stones were more common, so “dehydration caused it” belongs in the possible-explanation column, not the proven-cause column.

The current Wegovy label reported serious urolithiasis in 0.6% of treated patients and 0.4% of placebo patients in that trial.

Two honest limits:

1. Those numbers do not prove Wegovy caused each event.
2. They cannot rank Wegovy against another GLP-1 because the products were not compared head to head.

Why this section matters more than it looks

Kidney stones are one place where adequate fluid intake can matter for many people.

Not for everyone. If you have advanced kidney disease, heart failure, or a prescribed fluid limit, “drink more water” can be the wrong advice. Use the target your clinician gave you.

Stones do not feel like simple dehydration

Sharp pain in the side or back, blood in the urine, fever, chills, or pain with urination need medical evaluation. Fever plus a possible blocked urinary tract can be urgent. Do not try to solve that with an electrolyte drink and an article.

How do you lower your risk of GLP-1 kidney problems?

The clearest preventable pathway is letting severe stomach side effects turn into major fluid loss without telling your care team. The practical steps are following the prescribed titration, reporting persistent vomiting or diarrhea early, and making a sick-day plan before you need it.

We are not going to give you a water number

You have probably seen “drink 64 ounces” or “drink a gallon.” We are not doing that because people with advanced CKD, heart failure, or dialysis may have a prescribed fluid limit. A universal water target can hurt the exact reader most worried about kidneys.

Ask what fluid target applies to you. If you have no fluid restriction, the useful principle is simple: do not let ongoing stomach symptoms quietly turn into very low intake and very low urine output.

Report these early instead of toughing them out

• Vomiting that keeps going
• Diarrhea that keeps going
• Not being able to keep fluids down
• Nausea bad enough that you have almost stopped eating and drinking
• Much darker or much less urine
• Symptoms that became worse after a dose increase

The instinct to wait can turn a rough week into an urgent problem. Reporting a side effect is not the same as being taken off the medicine.

Follow the prescribed titration

GLP-1 doses rise gradually to improve tolerability. Do not jump ahead, double a missed dose, or build your own schedule. Use the instructions for your exact product and call the prescriber when the schedule is unclear.

Make a sick-day plan before you are sick

Ask now, while you feel fine:

• Who do I contact after hours?
• What symptoms mean urgent care instead of a portal message?
• What should I do about the next dose if I am vomiting?
• What is my fluid guidance during a stomach bug?
• Do any of my other medicines need a clinician-made sick-day plan?

Write the answers down. You will not want to figure this out at 2 a.m. while vomiting.

Keep your baseline where you can find it

Save your last creatinine, eGFR, and uACR with dates; your medicine list; and the prescriber's after-hours number. One note on your phone is enough.

For the symptom-by-symptom version, use our GLP-1 dehydration guide →

Do compounded GLP-1s carry the same kidney information?

No. A compounded semaglutide or tirzepatide product is not an FDA-approved finished drug. It does not have its own FDA-approved label, FDA-reviewed renal pharmacokinetics section, kidney-impairment dosing section, kidney indication, or FDA-approved Medication Guide. You cannot copy the kidney claims from Ozempic, Wegovy, Mounjaro, or Zepbound onto a compounded finished product.

We are an affiliate site. Plenty of providers in this market sell compounded GLP-1 programs. So let us be straight about what that means here.

FDA says a compounded drug may be appropriate when a patient's need cannot be met by an approved drug or when the approved drug is not commercially available. FDA also says compounded drugs are not FDA approved, so the agency does not review the finished compounded drug for safety, effectiveness, or quality before it is marketed.

Practically, for kidneys, that means the compounded finished product has:

• No FDA-reviewed section showing how kidney function changes its drug levels
• No FDA-approved dose rule for CKD, kidney failure, or dialysis
• No FDA-approved kidney-protection indication
• No FDA-approved Medication Guide with standardized kidney-warning language
• No right to borrow FLOW's outcome claim just because the vial is described as semaglutide

This is a statement about evidence and documentation. It is not proof that every compounded product is more harmful to the kidneys. We do not have evidence for that claim, and we are not going to make it.

Why dose accuracy matters here specifically

FDA has received reports of dosing errors with compounded injectable semaglutide. Some people measured the wrong amount; some clinicians miscalculated the dose. Some reported events required hospitalization. Reported symptoms included nausea, vomiting, diarrhea, abdominal pain, and constipation.

That is not a paperwork problem. Severe vomiting or diarrhea can lead to the exact fluid-loss pathway this page has been explaining.

As of May 31, 2026, FDA said it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Those are reports, not proven cases caused by the drug. FDA says it cannot always determine causation, and reports may also be undercounted because many state-licensed pharmacies are not required to report them to FDA.

If you use a compounded product and something goes wrong, have this ready:

• The exact name on the prescription label
• The concentration, such as milligrams per milliliter
• The amount you drew in milliliters or units
• The amount in milligrams, if your instructions state it
• The date and time you took it
• The vial, lot information, pharmacy, and prescriber
• A photo of the label and written dosing instructions

If the amount may be wrong, call your prescriber or Poison Help at 1-800-222-1222. Call 911 for collapse, a seizure, trouble breathing, or someone who cannot be woken.

We are not putting a provider link in this section. If a page tells you compounded products carry less reviewed evidence and then sells you one three lines later, you should not trust the page.

What if you do not have diabetes? Does any of this apply?

Yes, but the evidence is thinner. FLOW's hard kidney-outcome evidence applies to people with type 2 diabetes and CKD. SELECT found fewer kidney events with semaglutide 2.4 mg in people with overweight or obesity and heart disease but no diabetes. A separate 101-person randomized trial found a large drop in urine albumin over 24 weeks in people with obesity or overweight and CKD without diabetes. None of that answers what happens to a healthy weight-loss user's kidneys over 20 years.

If you use a GLP-1 only for weight loss and your blood sugar and kidneys are normal, you are still the reader least directly covered by kidney trials. You deserve to know that.

Here is the map:

The nondiabetic CKD trial fills one gap — not all of it

The 101-person trial matters because every participant had CKD and overweight or obesity without diabetes. After 24 weeks, semaglutide reduced uACR by 52.1% relative to placebo. Gastrointestinal adverse events were reported by 30 semaglutide participants and 15 placebo participants.

That is promising. It is also a short albumin-in-the-urine trial. It was not large or long enough to show whether semaglutide prevents dialysis, kidney failure, or death in this population.

About that tirzepatide number

You may see “tirzepatide reduced kidney events by 42%.” That comes from a post-hoc kidney analysis of SURPASS-4. Three limits belong beside it:

1. The kidney analysis was post hoc, not the trial's original main question.
2. The trial was open-label, so patients and clinicians knew which treatment was used.
3. Tirzepatide was compared with insulin glargine, not placebo or an SGLT2 inhibitor.

It is a real signal. It is not the same level of evidence as FLOW, and we will not present it as if it is.

What still applies whether you have diabetes or not

The dehydration pathway does not care why you take the medicine. If you are vomiting for days, having nonstop diarrhea, barely drinking, or barely urinating, your kidneys face the same short-term blood-flow problem.

That is the part worth planning for now.

What we actually verified

We built this page by reading the source documents, not by summarizing another health article. Here is exactly what the review included.

Label audit:

• Nine currently marketed stand-alone U.S. brand-label records: Ozempic; Wegovy injection/tablet; Rybelsus/Ozempic tablets; Zepbound; Mounjaro; Foundayo; Trulicity; Victoza; and Saxenda
• Two withdrawn exenatide reference labels: Byetta and Bydureon BCISE
• One current generic exception checked separately: FDA-approved generic exenatide, which carries the former Byetta kidney rule
• Current kidney-warning headings, renal dose wording, pharmacokinetic wording, hard cutoffs, dialysis or ESRD language, and kidney indications
• Archived 2024 labels to test whether kidney warnings were truly absent before the 2025 wording changes
• The Federal Register notice confirming that Byetta and Bydureon BCISE approvals were withdrawn effective September 3, 2025 after marketing ended

Clinical evidence:

• The 1.4-million-person VA outcome atlas and all four kidney hazard ratios
• FLOW and the current Ozempic kidney indication
• SELECT's kidney analysis in people without diabetes
• The 101-person randomized trial in nondiabetic CKD
• The five-year Danish SGLT2-versus-GLP-1 target-trial emulation
• SURPASS-4's post-hoc tirzepatide kidney analysis
• REMODEL's 52-week mechanistic work
• Kidney-transplant observational data
• Published case reports of kidney injury not explained by a simple dehydration story

Guidance and regulatory material:

• FDA's current page on unapproved and compounded GLP-1 products
• KDIGO kidney guidance
• National Kidney Foundation CKD and albuminuria categories
• Current Canadian Wegovy wording and UK renal-pharmacy guidance
• Ro's current public pricing, insurance, and service pages for the final access block only

What we did not do:

• Diagnose anyone or interpret an individual lab result
• Tell a reader to take, skip, lower, stop, or restart a dose
• Rank the medicines by kidney safety when no head-to-head evidence supports that ranking
• Compare separate adverse-event tables as if they came from one trial
• Turn a case report into an incidence rate
• Give one fluid target or one lab schedule to everyone
• Treat patient-forum posts or weight-loss testimonials as medical evidence
• Treat a provider's marketing claim as proof of a medical outcome

Our evidence order: current FDA label first, then FDA regulatory material, kidney-authority guidance, randomized trials, well-designed observational studies, case reports, and finally public patient language for understanding fears — never for proving risk.

Verification date: August 11, 2026. Label status, product availability, provider pricing, and regulatory pages can change. Recheck them before any material update.

Material change log

• August 11, 2026 — Initial publication. Reviewed nine currently marketed stand-alone U.S. brand-label records, two withdrawn exenatide labels, FDA-approved generic exenatide, archived warning language, kidney dosing statements, dialysis wording, the Ozempic kidney indication, current compounding information, and the cited clinical studies.

Found something that does not match a current label or primary source? Send the product, link, and section through our contact page. We check correction requests against the source and log material changes here.

What people are actually worried about

These are real words from public kidney-patient discussions. They are here because the fear is real, even when a forum cannot answer the medical question.

“Has anyone with kidney problems taken Ozempic? Has it helped the kidneys or just diabetes?”

“I am nervous to switch up my medications at this point.”

“After reading all replies I have decided not to take it… I sure as hell don't want to do anything else to hurt them.”

These quotes show what people worry about. They are not medical evidence. They do not prove that a GLP-1 caused anyone's kidney problem, and they should not outweigh a current label, a lab trend, or a clinician who can see the chart.

That third quote is the one that stays with us. Someone talked themselves out of a medicine a clinician had prescribed after reading comments from strangers.

You are allowed to be worried. You are allowed to ask hard questions. Bring the question back to the person who can see your medicines, your fluid limits, and your kidney numbers.

Frequently asked questions about GLP-1 kidney problems

Does Ozempic cause kidney problems?

Ozempic's current label warns about acute kidney injury caused by fluid loss from nausea, vomiting, or diarrhea; some reported cases required dialysis. The same label says no dose adjustment is needed for renal impairment, including kidney failure. It also has an FDA-approved indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and CKD. All three facts can be true at once.

Does Wegovy damage the kidneys?

Wegovy carries an acute kidney injury warning tied to volume depletion from stomach side effects. Its current merged injection/tablet label has no hard kidney cutoff, but it does not give the broad stand-alone ESRD dose sentence used in some other labels. Its current pharmacokinetic analysis describes people with eGFR 30 to under 90. Wegovy does not have an FDA kidney-protection indication.

Can Mounjaro or Zepbound affect kidney function?

Yes. Both tirzepatide labels warn about acute kidney injury due to volume depletion, and both say no dosage adjustment is recommended for renal impairment, including ESRD. That dose statement is pharmacokinetic guidance. It is not proof of long-term safety or benefit for every dialysis patient.

Does Foundayo have a kidney warning?

Yes. Foundayo's current label warns about acute kidney injury due to volume depletion. It says no dosage modification is recommended for renal impairment, including ESRD, and its pharmacokinetic analysis did not find a clinically meaningful effect from renal impairment. The label does not give a kidney-protection indication or dialysis-outcome evidence.

Is a low eGFR a reason you cannot take a GLP-1?

Not by itself for the nine currently marketed brand-label records in our table. None has a hard eGFR or creatinine-clearance cutoff. FDA-approved generic exenatide is the current exception and is not recommended in ESRD or severe renal impairment defined in its label as creatinine clearance below 30. The withdrawn Bydureon BCISE label used eGFR below 45. The exact product matters.

Can you take a GLP-1 on dialysis?

There is no class-wide yes or no. Several U.S. labels state no adjustment is needed in ESRD; Victoza and Saxenda note limited experience; the current Wegovy label uses narrower kidney-function data; and exenatide is not recommended in ESRD. Dialysis trials are limited, and fluid, nutrition, blood pressure, and transplant plans make this a nephrologist-level decision.

Can dehydration raise creatinine or lower eGFR?

Yes. Fluid loss can reduce blood flow to the kidneys. Creatinine may rise, and the calculated eGFR may fall. That does not tell you the cause or whether the change is permanent. A result drawn during or just after vomiting, diarrhea, heat illness, or very low intake needs clinical context and often repeat testing.

Should I skip my next dose after vomiting?

This page cannot clear or cancel your next dose. Call the clinician who prescribed it. The answer depends on how severe the symptoms are, whether you can keep fluids down, your kidney function, and your other medicines. Seek urgent in-person care instead of waiting for a portal reply if symptoms are severe or urine output is very low.

How often should kidney labs be checked on a GLP-1?

There is no universal “every three to six months” rule in the nine currently marketed labels we reviewed. They commonly tell prescribers to monitor kidney function when a patient has reactions that could cause fluid loss, especially during treatment start or dose escalation. A clinician may set a routine schedule for you because of CKD, diabetes, blood-pressure medicines, or past lab changes. That is individual care, not a class-wide interval.

Can GLP-1 medicines cause kidney stones?

There is a modest signal, not proven causation. The VA observational study found a 15% higher rate of nephrolithiasis in GLP-1 users than in usual-care users. One Wegovy outcomes trial reported urolithiasis in 1.2% of treated patients and 0.8% of placebo patients. Lower fluid intake is a plausible contributor, but neither result proved why the stones happened.

Is one GLP-1 safest for the kidneys?

No defensible head-to-head ranking exists. The drugs were tested in different people, at different doses, over different time periods. What the evidence does support is narrower: exenatide has the clearest kidney-function restriction, while Ozempic is the only product in this comparison with an FDA-approved kidney-protection indication.

Can a GLP-1 protect kidneys in someone without diabetes?

Possibly, but the evidence is not as strong as FLOW. SELECT found fewer kidney-composite events with semaglutide 2.4 mg in people with overweight or obesity and cardiovascular disease without diabetes. A 101-person randomized trial in nondiabetic CKD found a 52.1% relative reduction in uACR over 24 weeks. Neither study gives a 20-year answer for a healthy weight-loss user.

Is kidney damage from a GLP-1 permanent?

Not always. Acute kidney injury can improve when the cause is found and treated, but recovery depends on the cause, severity, duration, and baseline kidney health. Interstitial nephritis, obstruction, infection, stones, and advanced CKD are different problems. A repeat lab and clinical evaluation are what answer the question for one person.

Are compounded GLP-1s worse for the kidneys?

There is no evidence that lets us rank compounded products against approved products by kidney harm. What is verified is that a compounded finished product is not FDA approved and has no FDA-approved renal pharmacokinetics section, CKD dose rule, kidney indication, or Medication Guide. FDA has also reported dosing errors and adverse events with compounded injectable semaglutide and tirzepatide. That is a reason to demand exact concentration and dosing instructions, not a reason to invent a comparative risk number.

Should I drink electrolyte drinks on a GLP-1?

Not automatically. Many products contain sodium, potassium, or sugar. People with CKD, heart failure, diabetes, or a prescribed fluid or potassium limit may need different advice. Ask what fluid and electrolyte plan applies to you. An electrolyte drink is not a treatment for severe vomiting, little urine, confusion, fainting, or suspected kidney injury.

Still not sure which GLP-1 program is right for you?

If you are stable, have no warning symptoms, and are trying to choose an access route rather than solve an urgent kidney problem, that is a fair next question.

Our free matching quiz asks five questions about your goals, budget, insurance, and preferences. It does not diagnose kidney disease or approve a medicine. A licensed clinician makes treatment decisions.

Do not use the quiz for severe symptoms, a possible emergency, or instructions about your next dose. Contact your prescriber or get urgent care instead.

If your real problem is access, not safety

Some readers reach the end and realize the question is not “which medicine is safest for my kidneys?” It is “how do I get an FDA-approved option and handle the insurance work?”

That is where a provider comparison belongs — after the safety question has been answered, not inside the warning sections.

Ozempic is the one product in this article with an FDA-approved kidney indication, but that indication is only for adults with type 2 diabetes and CKD. A telehealth intake cannot replace a nephrologist or the clinician already managing your kidney disease.

If you have CKD stage 4 or 5, are on dialysis, have a kidney transplant, or just had a major kidney-lab change, start with the clinician who knows those numbers. Use the access service after the medical plan is clear.

Weight Loss Provider Guide is an independent comparison resource. We may earn a commission if you use certain provider links. You pay nothing extra. Any commission does not change the label findings, warnings, or study results above.

Sources

Current and archived U.S. prescribing information

• Ozempic prescribing information — DailyMed
• Wegovy injection and tablet prescribing information — DailyMed
• Rybelsus and Ozempic tablets prescribing information — DailyMed
• Zepbound prescribing information — DailyMed
• Mounjaro prescribing information — DailyMed
• Foundayo prescribing information — DailyMed
• Trulicity prescribing information — DailyMed
• Victoza prescribing information — DailyMed
• Saxenda prescribing information — DailyMed
• Byetta archived reference label — DailyMed
• FDA-approved generic exenatide prescribing information — DailyMed
• Bydureon BCISE archived reference label — DailyMed
• Victoza November 2024 FDA label — archived PDF
• Wegovy 2024 FDA label — archived PDF
• Rybelsus 2024 FDA label — archived PDF
• Bydureon BCISE 2024 FDA label — archived PDF
• FDA withdrawal notice for Byetta and Bydureon BCISE — Federal Register, August 4, 2025

FDA and kidney guidance

• FDA's concerns with unapproved GLP-1 drugs used for weight loss
• FDA alert on dosing errors with compounded injectable semaglutide
• National Kidney Foundation: How to classify CKD
• KDIGO 2024 Clinical Practice Guideline for CKD
• UK Renal Pharmacy Group: GLP-1 receptor agonist prescribing in CKD
• Canadian Wegovy product monograph

Clinical evidence

• Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Medicine. 2025;31:951–962.
• Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine. 2024;391:109–121.
• Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature Medicine. 2024.
• Apperloo EM, Gorriz JL, Soler MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes. Nature Medicine. 2025.
• Jensen SK, Heide-Jørgensen U, Andersen IT, et al. SGLT2 inhibitors vs GLP-1 receptor agonists for kidney outcomes in individuals with type 2 diabetes. JAMA Internal Medicine. 2026.
• Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in SURPASS-4. The Lancet Diabetes & Endocrinology. 2022;10:774–785.
• REMODEL trial design and mechanistic endpoints — PubMed
• Semaglutide and kidney-transplant outcomes — PubMed
• Acute kidney injury associated with semaglutide — Kidney Medicine
• Semaglutide-associated acute interstitial nephritis — Kidney Medicine

Patient-language and provider verification sources

• HealthUnlocked discussion: “Ozempic, anyone taking it?”
• HealthUnlocked discussion: “Ozempic”
• Ro Body current pricing
• How Ro's weight-loss program and insurance support work